Postmortem brain tissue examination revealed that AD patient samples had significantly lower levels of IGF2 mRNA (Steen et al., 2005) and protein (Pascual-Lucas et al., 2014) in the hippocampus and hypothalamus than samples from patients without AD did. This evidence concerns the gene IGF2 and Alzheimer disease.